Hill September 29, 2023
Joseph Choi

The deadline for drugmakers to sign agreements to negotiate with Medicare on pricing is fast approaching. Major drugmakers have until Sunday to sign an agreement to participate in the program or potentially face heavy taxes and lose their ability to sell through Medicare.

With courts yet to impose an injunction in a spate of pending lawsuits, several of the companies producing the 10 drugs selected for Medicare negotiations appear ready to move ahead with negotiations.

Merck, whose diabetes treatment Januvia was selected, made it known it will sign an agreement with the Centers for Medicare & Medicaid Services (CMS) “under protest.”

“While we disagree on both legal and policy grounds with the IRA’s new program, withdrawing all of the company’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Expert Discusses Pharmacy Deserts, Expanding Pharmacy Access
New migraine drugs less effective than previous generation of triptan meds: BMJ study
Drugmaker seeks $157.5M in IPO, placement
Q&A: PBM Legislation “Highly Likely” to Pass This Year
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement

Share This Article